Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors

Xenobiotica

Volumn 42, Issue 5, 2012, Pages 456-465

  Liederer, Bianca M ^a   Liu, Xingrong ^a   Berezhkovskiy, Leonid M ^a   Cain, Gary ^a   Ding, Xiao ^a   Gaudino, John ^b   Kaus, Robert ^b   Plise, Emile G ^a   Sutherlin, Daniel P ^a   Harstad, Eric B ^a  

^a GENENTECH INC   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

absorption; disposition; enantiomers; MET; pharmacokinetics; stereoselectivity; tissue distribution; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; N [4 [3 (1 ETHYL 3,3 DIFLUOROPIPERIDIN 4 YLAMINO) 1H PYRAZOLO[3,4 B]PYRIDIN 4 YLOXY] 3 FLUOROPHENYL] 2 [4 FLUOROPHENYL] 3 OXO 2,3 DIHYDROPYRIDAZINE 4 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN; CHIRALITY; DRUG PENETRATION; ENANTIOMER; FEMALE; HAPLORHINI; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; RAT; SINGLE DRUG DOSE; STEREOCHEMISTRY; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; BODY WEIGHT; CELL LINE; CELL MEMBRANE PERMEABILITY; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; MACACA FASCICULARIS; MALE; MICE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TIME FACTORS;

MUS; RATTUS;

EID: 84859323533     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.632697     Document Type: Article

References (16)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640)
2. Boulton DW, Fawcett JP. (1996). Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 41:35-40. (Pubitemid 26009908)
3. Burke D, Henderson DJ. (2002). Chirality: A blueprint for the future. Br J Anaesth 88:563-576. (Pubitemid 34285208)
4. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
5. Downes H, Perry RS, Ostlund RE, Karler R. (1970). A study of the excitatory effects of barbiturates. J Pharmacol Exp Ther 175:692-699.
6. Drayer DE. (1986). Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin Pharmacol Ther 40:125-133. (Pubitemid 16048872)
7. Hamadeh HK, Todd M, Healy L, Meyer JT, Kwok AM, Higgins M, Afshari CA. (2010). Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors. Chem Res Toxicol 23:1025-1033.
8. Hayball PJ, Wrobel J, Tamblyn JG, Nation RL. (1994). The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. Br J Clin Pharmacol 37:75-78. (Pubitemid 24204586)
9. Hutt AJ, Tan SC. (1996). Drug chirality and its clinical significance. Drugs 52 Suppl 5:1-12. (Pubitemid 26379061)
10. Islam MR, Mahdi JG, Bowen ID. (1997). Pharmacological importance of stereochemical resolution of enantiomeric drugs. Drug Saf 17:149-165. (Pubitemid 27421277)
11. Liu X, Yao W, Newton RC, Scherle PA. (2008). Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17:997-1011.
12. Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657-3660. (Pubitemid 44000247)
13. Smith SW. (2009). Chiral toxicology: It's the same thing.only different. Toxicol Sci 110:4-30.
14. Tucker GT, Lennard MS. (1990). Enantiomer specific pharmacokinetics. Pharmacol Ther 45:309-329. (Pubitemid 20003435)
15. White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. (1985). Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 57:197-203. (Pubitemid 15093411)
16. Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250-254. (Pubitemid 40175478)